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ABSTRACT
Using microRNA array analyses of in vitro HIV-1-
infected CD4
+ cells, we find that several host
microRNAs are significantly up- or downregulated
around the time HIV-1 infection peaks in vitro.
While microRNA-223 levels were significantly en-
riched in HIV-1-infected CD4
+CD8
  PBMCs,
microRNA-29a/b, microRNA-155 and microRNA-21
levels were significantly reduced. Based on the po-
tential for microRNA binding sites in a conserved se-
quence of the Nef-30-LTR, several host microRNAs
potentially could affect HIV-1 gene expression.
Among those microRNAs, the microRNA-29 family
has seed complementarity in the HIV-1 30-UTR, but
the potential suppressive effect of microRNA-29 on
HIV-1 is severely blocked by the secondary struc-
ture of the target region. Our data support a
possible regulatory circuit at the peak of HIV-1 rep-
lication which involves downregulation of
microRNA-29, expression of Nef, the apoptosis of
host CD4 cells and upregulation of microRNA-223.
INTRODUCTION
MicroRNAs (miRNAs) are 21–23nt long regulatory,
non-coding, small RNAs that repress target gene transla-
tion through base pairing to complementary sequences in
the 30-untranslated region (30-UTR) of targeted tran-
scripts. Although the role of miRNAs in modulating
HIV-1 infection is unclear, early on it was speculated
that miRNAs could use the RNAi mechanism to directly
target the viral RNA (1). MiRNAs that target HIV-1
could be grouped as those encoded by the host or those
encoded by HIV-1.
The potential involvement of host miRNAs in HIV in-
fection is intriguing, particularly given the documented
participation of host miRNAs in the replicative cycles of
other mammalian viruses. For instance, host miR-32 re-
stricts primate foamy virus 1 replication (2) and host
liver-speciﬁc miR-122 facilitates the replication of the
hepatitis C viral RNAs (3). Several cellular miRNAs are
predicted to target conserved regions of the HIV-1 genome
(4), whereas Tat was reported to globally downregulate
the host miRNA pathway by inhibition of Dicer activity
(5–6). It has also been reported that downregulation of the
miR-17/92 cluster and upregulation of its target PCAF
facilitates HIV-1 infection (7). A published comparison
of miRNA expression in activated versus resting CD4
+
T lymphocytes concluded that several host miRNAs
which target the Nef-30-LTR region may contribute to
HIV-1 latency (8). Speciﬁc signature miRNAs were asso-
ciated with the classiﬁcation of HIV-1 infection based on
miRNA microarray proﬁling of PBMCs isolated from
HIV-1 seropositive individuals (9). Deregulation of host
miRNAs in human T-lymphotropic virus type 1
(HTLV-1) patients of adult T-cell leukemia and HTLV-1
transformed T lymphocytes were also reported (10,11).
Finally it has been reported that miR-29a can target
HIV-1 and direct HIV-1 RNAs into P bodies (12).
Given the uncertainties of the possible roles miRNAs
might play in HIV-1 infection, we have focused our inves-
tigations on the up and down regulated cellular miRNAs
in HIV-1 infection at the time that the virus loads peak
and CD4
+T cells start to decline (13,14). To this end, we
employed a comprehensive approach to delineate possible
connections between cellular miRNA changes, CD4
+ cell
death and viral load. On the one hand, in order to identify
miRNAs that become deregulated upon HIV-1 infection,
we carried out HIV-1 infections and derived miRNA
microarray proﬁles from infected and uninfected
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HIV-1 sequence for seed matches to annotated human
miRNAs represented in miRBase 12 and found thousands
of potential host miRNA target sites in the HIV-1
genome. In this study, we rank these potential sites
based on their conservation among HIV-1 clades,
miRNA/target binding energies, expression proﬁles in
host cells and their target locations within the HIV-1
genome. These analyses have allowed us to derive a list
of the most promising candidate cellular miRNAs that
target HIV-1 RNA in CD4
+ cells. Based on validation
of results from multiple experiments, we focused our
efforts on studying the possible roles of miR-29 and
miR-223 in HIV-1 infection. We ﬁnd that while both
miR-29 and miR-223 can potentially suppress HIV-1 in-
fection, their actual binding to the HIV-1 30-UTR is
impaired by the structure of the target region. Since the
potential target for these miRNAs is a highly conserved
region of the HIV genome, our results suggest that the
structural features of this region have been evolutionarily
selected for a thus far unknown functional role which for-
tuitously also provides an escape from host miRNA-
mediated inhibition of HIV gene expression. Our study
represents the most comprehensive analysis of HIV-1
and host miRNA interactions to date.
MATERIALS AND METHODS
CD4
+CD8
  isolation
Oligos used in this paper for plasmids construction and
Northern Blotting are listed in Supplementary Table S3.
CD4
+ PBMC cells were isolated from apheresis blood
cones provided by the City of Hope Blood Donor/
Apheresis Center, by using PBMC (Histopaque 1077,
Sigma-Aldrich)/PBGC (Histopaque 1119, Sigma-
Aldrich) ﬁcoll gradients. The ﬁcoll gradients were
layered below the blood in a 50ml tube and centrifuged.
The CD4
+ cells were further depleted of CD8
+ cells by
negative selection using M-450 CD8 Dynabeads
(Invitrogen). CD4
+ cells were added to PBS plus washed
Dynabeads at a ratio of at least four Dynabeads to one
cell. The tube was placed next to a magnet and the
CD4
+CD8
  cell population was pipetted from the tube.
The cells were washed and cultured in activated
ActiCyte-TC media (BioE).
Cell culture and transfection
HEK-293, HeLa and HeLa-T4 were maintained in high
glucose (4.5g/l) DMEM supplemented with 2mM glutam-
ine, 10% FBS and 2mM penicillin/streptomycin. Jurkat,
NB4, HL60, CEM-GFP, U937 and CEM cells were grown
in RPMI1640 supplemented with 2mM glutamine, 10%
FBS and 2mM penicillin/streptomycin.
Jurkat, HL-60 and CEM cells were purchased from
ATCC. NB4 cells were kindly provided by Dr Sigal
Gery (Cedars-Sinai Medical Center, Los Angeles, CA,
USA). The following cell lines were obtained through
the NIH AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH: HEK-293,
HeLa, Hela-T4, CEM-GFP and U937 from Dr Thomas
Folks; pNL4-3.Luc.R–E– from Dr Nathaniel Landau.
Transfection of HEK-293 and HeLa were performed
with Lipofectamine 2000 (Invitrogen) in 24-well plates.
Forty eight hours post-transfection, the cells were lysed
and were analyzed with the Dual Luciferase reporter assay
kit (Promega) on a Veritas Microplate Luminometer
(Turner Biosystems).
Transfection of HeLa-T4 cells with synthetic
Pre-miR
TM miRNA precursor molecule and Anti-miR
TM
miRNA inhibitors were performed with siPORT
TM
NeoFX
TM transfection agent. The protocol provided by
Ambion and 100nM of the pre/anti-miRs were used.
Retinoic acid treatment
Cells were treated with 10mM all-trans retinoic acid
(ATRA, Sigma) for 24, 48, 72 and 96h. RNA and cell
extracts were prepared at each time point.
Apoptosis
Cisplatin and Campothecin (Sigma) were use to induce
apoptosis in CEM, NB4, HL60, U937 and Jurkat cells.
Five micromolar apothecia and 20mM cisplatin were
used for the treatment. Apoptosis was detected with
annexin V-PE apoptosis detection Kit from BD
Pharmingen
TM.
HIV-1 infection
HIV-1 infection in CEM, Jurkat and U937 cells were per-
formed at 0.01MOI (multiplicity of infection).
CD4
+CD8
  cells were infected the same way as CEM
cells except they were washed with ActiCyte-TC basal
media and were cultured in ActiCyte-TC activation
media. Every 3 days, half of the cells were collected for
cell extracts and RNAs, and equal amount of fresh
medium were replenished. Cells without viruses were
treated the same way and were used as a control for
each time point. Infection was followed by microscopic
analyses of EGFP expression in a CEM-GFP cell line
and P24 assays of supernatants from infected cells.
Primary miRNA expression
The pri-miRNA expression vector, fU1-miR, was con-
structed as previously reported (15). The miRtron expres-
sion vector PGK-miR was constructed the same way as
the fU1-miR: U1 was replaced with a mouse PGK
promoter and the U1 termination sequence was replaced
with a BGH poly (A) sequence.
Dual Luciferase reporter assays
Reporters were constructed by inserting annealed target
sequences or PCR ampliﬁed target gene’s 30-UTR into the
XhoI/SpeI or XhoI/NotI sites of the 30-UTR of Rluc gene
in psiCheck2.2, 3.2 or 4.2. The assay was performed as pre-
viously described (15). The relative ratio of Rluc/Fluc was
used to measure the repression efﬁciency. Transfection
results were obtained by averaging the results from at
least three individual transfections with two replicates
each.
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All sequences for a speciﬁc gene or region of HIV-1 and
SIVcpz were retrieved from the HIV databases (http://
www.HIV.lanl.gov/content/index).
MiRNA target sites and sites accessibility on
HIV-1 NL4-3
We used PITA to predicate all target sites of 866 human
miRNAs in miRBase 12 on HIV-1 pNL4-3. The site ac-
cessibility was also calculated with PITA. We used 6nt as
the seed, and any G:U pair or any mismatch were not
allowed.
Cell cycle analysis
HeLa cells were used for the cell cycle study. We followed
the published protocol (16). Cell synchronization was
monitored by ﬂow cytometry of propidium iodide-stained
(100mg/ml) cells.
RNA isolation, northern blot
RNA isolation and northern blot were carried out as pre-
viously reported (15). Brieﬂy, RNA was isolated with
RNA STAT-60 (Tel-Test Inc.). DNA oligonucleotide
probes were labeled with g-
32P-ATP. The hybridization
was performed overnight in PerfectHyb
TM Plus
Hybridization Buffer from Sigma. U2 or U6 snoRNAs
were used as RNA loading controls.
Lentivirus production
A detailed protocol for generating lentiviral vectors was
previously published (17). Lentiviruses were used to infect
cells and EGFP positive clones were sorted by ﬂow cyto-
metry. Stable expression of mature miRNAs was analyzed
by northern blotting.
Immunobloting
Western blot analyses were carried as previously reported
(18).
MiRNA microarray and data processing
Total RNA was initially extracted using STAT-60 (Tel-
Test Inc.) followed by puriﬁcation using the RNeasy
column (Qiagen) with a modiﬁed protocol (RNeasy kit
manual). Samples were labeled using the Exiqon
miRCURY LNA
TM arrays, Hy3/Hy5 Power Labeling
Kit which enzymatically adds a ﬂuorescent label (Hy3 or
Hy5) to the 30-end of the miRNAs. One microgram of
total RNA with control spiked-in oligos was processed
per the company’s recommendations. The labeled products
were then hybridized onto an array at 56 C for 16h in a
SureHyb hybridization chamber (Agilent), and an Agilent
hybridization oven. The arrays were washed as recom-
mended by Exiqon. Array images were scanned with an
Agilent microarray scanner and feature extraction was
used for the data extraction.
Preprocessing of raw data and statistical analyses were
performed using the Bioconductor package LIMMA and
R programming environment. Background correction was
performed using the ‘normexp’ method implemented in
the LIMMA package to adjust the local median back-
ground estimates (19). The background-corrected inten-
sity data were normalized using the Print-tip group
Lowess method to remove the bias within each array.
When the dye-swap pairs were present, the normalized
ratios between treated samples and control samples of
the two dye-swap slides were averaged. MiRNAs that
were up or down regulated more than 1.5-fold in at least
one of the time points were selected as potential targets.
Hierarchical clustering of the targets was performed by
Cluster V2.1 with Pearson correlation and average
linkage method (20). Clustering results were visualized
using Java TreeView V1.1.3 (21).
MiRNA quantiﬁcation with TaqMan MicroRNA Assay
The miRNA array data was validated with an individual
TaqMan MicroRNA Assay kit from Applied
Biosystems. Using the protocol recommended by the
manufacturer. A BIO-RAD iCycler Thermal Cycler was
used for the PCR quantiﬁcation analyses. Each reaction
(20ml) was spiked with 1mlo f1mM ﬂuorescein calibration
dye (BIO-RAD). The comparative Ct method (fold
change=2
 Ct) was used to calculate the changes of
the tested miRNAs (22). MiR-142-3p was used as the
internal control. We choose miR-142-3p as the control
because of its high expression levels and minor variations
in all our array or northern blot experiments.
RESULTS
MiRNA proﬁles in HIV-1-infected cells
MiRNA proﬁles were derived for HIV-1 IIIB infected
CD4
+CD8
  PBMCs, CEM and Jurkat cells. Four array
experiments using three versions (7.0, 9.2 and 11.0) of the
Exiqon miRCURY LNA
TM arrays were performed using
three different sets of HIV-1-infected PBMC cell samples.
Using the miRCURY array versions 7.0 and 9.2, we
observed that cellular miRNAs miR-21, 26a, 155, 29a,
29b and 29c were signiﬁcantly downregulated (Figure 1a
and Supplementary Table S1a). In the miRCURY array
version 11, in addition to detecting downregulation of the
cellular miR-21, 26a, 155, 29a, 29b and 29c levels, we also
observed miR-223 to be upregulated upon HIV-1 infection
(Supplementary Table S1b). TaqMan miRNA RT-PCR
results conﬁrmed the downregulation of miR-21, 155,
29a, 29b and 29c and upregulation of miR-223 in HIV-1
infected versus uninfected samples (Figure 1b,
Supplementary Figure S1).
We next proﬁled miRNA expression in HIV-1 IIIB-
infected CEM and Jurkat cells using the miRCURY
array version 11. In addition, we performed northern
blot analyses of candidate deregulated miRNAs from
total RNAs derived from HIV-1 IIIB-infected CEM and
Jurkat cells over a 21-day time course of infection.
The magnitude of the miRNA changes in the CEM and
Jurkat array data were much smaller than in PBMCs. This
result was supported by the northern blot analyses
(Supplementary Figure S2). However, we consistently
observed upregulation of miR-223, downregulation of
Nucleic Acids Research,2012, Vol.40, No. 5 2183miR-29 and miR-155 in PBMCs, CEM and Jurkat cells
(miR-155 expression levels in Jurkat cells are very low as
revealed by northern blots and the array) (Supplementary
Table S1b and Supplementary Figure S2b). Northern blot
analyses conﬁrmed the downregulation of miR-29 and
miR-155, while miR-223 upregulation commenced
around Day 12 post-infection in CEM and Jurkat cells.
HIV-1 p24 assays of supernatants from the infected
samples and GFP ﬂorescent signal levels in CEM-GFP
HIV-1 reporter cells infected under the same conditions
showed the viral load peaking around this time as well
(data not shown).
Cellular miRNAs that potentially target HIV-1
We next searched for ‘seed sequences’ for the cellular
miRNAs in the HIV-1 genome. MiRNA target site
studies have revealed the ‘seed sequence’, deﬁned as the
nucleotides from position 2 to 7–8 from the 50-end of
miRNAs, as being critical for the miRNA/target inter-
action (23,24). For these analyses we used the computer
program PITA (25) to scan all seeds of cellular miRNAs
in HIV-1 pNL4-3 (NCBI accession numbers M19921
and AF324493), as well as a consensus sequence of the
Nef-30-LTR across all HIV-1 strains in the 2007 HIV-1
sequence database. PITA generated 2186 seed matches
(6–8-mer) to the 866 human miRNAs cataloged in
miRBase 12 within the 9.7 KB long NL4-3 genome.
Of these, 219 are in the 1.2 KB Nef-30-LTR fragment
(Table 1).
We next focused on host miRNA target sites in the
Nef-30-LTR region, which serves as the 30-UTR of all
HIV-1 transcripts. We further ﬁltered the 257 seeds in
the consensus Nef-30-LTR sequence from the PITA
screen according to the following criteria: cloned
Figure 1. MicroRNA microarray and RT-PCR detect cellular miRNA in HIV-1-infected RNA samples. (a) Heat map of deregulated miRNAs in
HIV-1 infected PBMCs. Partial microarray data for the deregulated miRNAs in PBMCs was classiﬁed and is shown as a heat map. Cellular miRNAs
miR-21, 26a, 155, 29a, 29b, 29c were among the downregulated miRNAs upon HIV-1 infection. (b) TaqMan miRNA RT-PCR assays of miR-21,
155, 29a, 29b, 29c and 142-3p in HIV-1 IIIB infected versus uninfected CD4
+CD8
  PBMC cells. Assays were performed for three infections: Days 3,
7, 10 and 16 for December 2006 infection; Days 3, 6, 9, 12, 15 and 18 for March 2008 infection; Days 3, 12 and 15 for June 2008 infection. The
comparative Ct method (fold change=2
 Ct) was used to calculate the changes of the tested miRNAs. Ct represents the difference between
each miRNA in infected versus uninfected samples and was normalized to miR-142-3p in the same samples. Each bar in the y-axis represents
the average of tested miRNA changes that were plotted by the week (x-axis): Day 3 through 7 as Week 1; Day 9 through 14 as Week 2; Day 15
through 21 as Week 3. The error bar represents STDEV. (RT-PCR results for each individual miRNAs at different days were shown in
Supplementary Figure S1).
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naive CD4 T cells (Supplementary Figure S3a) (26,27);
target site sequence conservation among HIV-1 clades;
and calculated miRNA/target sequence binding energies
(duplex in Tables 2 and 3). This process yielded a
group of host miRNAs—miR-15a, 15b, 16, 24, 29a, 29b,
150 and 223 that may directly target the HIV-1
Nef-30-LTR region (Supplementary Figure S3b and c).
Among these miR-29a and -29b are those miRNAs with
the strongest binding energies and their target site is
located in the most highly conserved region of the
Nef-30-LTR (Figure 2a and b).
When we mapped the miR-223 and miR-29 sites in the
NL4-3 genome, we noticed that the miR-29 seeds are very
close to the miR-223 seeds and actually overlap with the
region (9194-9217) encoding the putative HIV-1 derived
miRNA N367 (Table 4 and Figure 2a) (28,29). Given the
intriguing potential for miRNA regulation in this region
we performed reporter assays as well as HIV-1 p24 antigen
assays to examine the potential miR-223 and miR-29a/b
suppressive effects on HIV-1 replication.
We ﬁrst performed reporter assays by co-transfection of
the miRNAs with the pNL4-3-Luc vector. This reporter
construct containing a Fireﬂy luciferase (Fluc) gene was
created by in-frame insertion of the Fluc coding sequence
into the pNL4-3 Nef gene. A stop codon was also inserted
immediately following the Fluc coding sequence (30,31).
The miR-223 and miR-29 target sites are downstream of
this stop codon in the 30-UTR.The co-transfection results
showed miRtron-1224, one of the best potential miRNAs
predicted by PITA that can target NL4-3 Nef-30-LTR,
which has a 8-mer target seed (position 8979 of NL4-3;
Table 3) located  200nt upstream of the miR-29 target
site in the 30-LTR, provided repression levels of 20–30%.
In contrast, miR-223 only resulted in 5–10% repression.
Interestingly, miR-29 triggered a much stronger suppres-
sion ranging from 30% to 40% (Figure 3a). We next per-
formed HIV-1 p24 assays following co-transfection of
HIV pNL4-3 proviral DNA with ectopically expressed
pri-miRNAs 223 or 29 in HeLa-T4 cells. The results of
these transfections showed that ectopic expression of
miR-29 resulted in  40–60% reduction of p24 levels
(Figure 3b). In order to rule out the possibility that the
expressed pri-miRNA may not produce sufﬁcient levels of
mature miRNAs for efﬁcient target knockdown, we
co-transfected the synthetic Pre-miR
TM miRNA precursor
molecules with the pNL4-3 proviral DNA in HeLa-T4
cells. We also carried out experiments with HeLa-T4
cells ﬁrst transfected with the pre-miRs followed by
HIV-1 IIIB infection (Figure 3c). The data from these ex-
periments were consistent with the plasmid co-transfection
data. Anti-miR
TM miRNA inhibitors were used to inacti-
vate the miRNAs. The anti-miR results show that
knockdown of endogenous miR-29a/b led to enhanced
HIV-1 infection as measured by p24 production. In
contrast, knockdown of miR-223 had no effect. The
later result is not surprising since miR-223 levels are ex-
tremely low in the HeLa-T4 cells and are undetectable in
northern blots (Figure 3c).
Host factors as miRNA targets and their role in HIV-1
infection
Although host miRNAs may target the HIV-1 RNA
genome, they have host genes as their normal biological
targets. Some of the natural targets could be important for
HIV-1 infection (7,8,32). Again, we focused our efforts on
targets for miR-223 and miR-29.
By searching through the miR-223 targets predicted by
miRanda (33), TargetScan (34) and PicTar (35), several
major transcription factors were selected as candidates
for regulation by miR-223 which could potentially play
a role in HIV-1 infection. We fused the 30-UTRs of
these candidate genes with the Rluc reporter in the
psiCheck vector. The reporter assays showed Sp3 and
LIF were responsive to the presence of miR-223 in
HEK293 cells. All-trans-retinoic acid (ATRA) can
induce miR-223 expression in NB4 cells and target
NF-1A (36). This was used to validate Sp3 and LIF as
miR-223 targets (Supplementary Figure S4). We previous-
ly validated RhoB as an miRNA-223 target (18). RhoB
functions as an anti-apoptosis gene and can activate the
Table 2. Cellular miRNA candidates for targeting the HIV-1
Nef-30-LTR (see excel ﬁle S2 for the complete data)—Cellular
miRNAs potentially targeting the consensus sequence of the
HIV-1 Nef-30-LTR were screened by PITA
Host miRNA Position Seed Gduplex Gopen G
hsa-miR-29b 491 8:0:0  23.3  19.22  4.07
hsa-miR-29a 491 8:0:0  22.1  19.22  2.87
hsa-miR-24 120 8:0:0  20.24  9.27  10.96
hsa-miR-24 1003 7:0:0  18.07  12.94  5.12
hsa-miR-150 1010 7:0:0  17.98  15.33  2.64
hsa-miR-24 586 6:0:0  16.09  14.53  1.55
hsa-miR-16 958 6:0:0  14.2  16.89 2.69
hsa-miR-15a 958 6:0:0  12.41  16.89 4.48
hsa-miR-15b 958 6:0:0  10.75  16.89 6.14
In the seed column of the Table, 8:0:0 represents the target site as an
8-mer seed with no mismatches, (middle ‘0’) and zero G:U wobble pairs
(right side ‘0’). Based upon the Gduplex for a miRNA and a target
site, and the expression levels of the miRNA’s represented in http://
www.microrna.org/microrna/home.do, the candidate host miRNAs that
could effectively target the HIV-1 Nef-30-LTR are miR-24, miR-15a/b,
miR-16, miR-150 and miR-29a/b (Supplementary Figure S3).
Table 1. Cellular miRNA candidates for targeting the HIV-1
Nef-30-LTR (see excel ﬁle S2 for the complete data)—summary
of seed matches in HIV-1 NL4-3 and the consensus sequence
of the Nef-30-LTR
Seed NL4-3 Nef-30-LTR
(NL4-3)
Nef-30-LTR
(consensus)
6-mer 1576 147 191
7-mer 464 55 47
8-mer 146 17 19
Sum 2186 219 257
The HIV-1 NL4-3 Nef-30-LTR and the consensus sequence of the
Nef-30-LTR were used to scan potential binding sites for human
miRNAs documented in miRBase 12 (see Supplementary Table S2
for the complete data). The 6-mer seed (positions 2–7), 7-mer seed
(positions 2–8) and 8-mer seed (positions 2–9) were scanned.
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that RhoB is downregulated in HIV-1-infected cells
obtained from patients (39). Sp3 can repress HIV-1 LTR
activity directly and can also activate APOBEC3G which
is a host viral restriction factor (40,41). LIF can restrict
HIV-1 replication and has been reported to be down-
regulated in early HIV-1 infection (42–44). Therefore
miR-223 could function as a negative factor in HIV-1 in-
fection by reducing RhoB mediated activation of the
AKT-NFkB pathway. This miRNA could also function
as a positive factor in HIV-1 infection via targeting HIV-1
suppressive Sp3 and LIF.
MiR-29 targets include Mcl-1, DNMT 3A/B, Tcl1, p85
(the regulatory subunit of PI3 kinase) and CDC42
(45–48). Mcl1 is an anti-apoptosis protein and its over-
expression results in B cell lymphomas (49). This protein
could be upregulated during HIV-1 infection to inhibit
viral triggered apoptosis. By targeting p85 a and
CDC42, miR-29 can upregulate p53 levels and induce
apoptosis in a p53-dependent manner. By targeting
CDC42, miR-29 may play a role in cell cycle control
(48). CDC42 is required for Nef associated cellular serine
kinase activity (50–53). Upregulation of DNMT 3A/B
may trigger global DNA methylation thereby epigeneti-
cally silencing expression of immune system genes involved
in the host viral defense mechanism (54). Intriguingly,
upregulated DNMT 3A/B may also methylate the LTR
region of integrated HIV-1 thereby silencing the viral LTR
promoter activity, which could contribute to HIV-1
latency. Tcl1 is an AKT kinase coactivator that can
enhance AKT kinase activity (55–57), possibly facilitating
HIV-1 infection when upregulated. Therefore, miR-29’s
role in HIV-1 infection via regulation of cellular target
expression may be very complex.
HIV infection in cell lines ectopically expressing miRNAs
Since miRNAs can target both HIV-1 and host factors,
HIV-1 regulation by miRNAs could be the result of a
combination of directly targeting the viral RNA and the
indirect effects of targeting host factors. The time frames
of transient transfection may be insufﬁcient to observe the
repression effect of miRNAs on HIV-1 replication.
Therefore, we generated CEM cell lines that stably express
miR-223, miR-29a and miR-29b and challenged them with
HIV-1 IIIB infection (Supplementary Figure S5a). Despite
several attempts, we only observed very modest suppres-
sion by miR-223, miR-29a or miR-29b (Supplementary
Figure S5b). It has been reported that HIV-1 can escape
RNAi by mutations in the siRNA target (58) or via chang-
ing local structures that include the siRNA target (59)
[reviewed in reference (60)]. We therefore isolated and se-
quenced the target regions of the miRNAs in virviral
RNAs at 6 weeks of infection. The results showed that
the lack of strong suppression was not due to viral escape
mutants in the miRNA binding sites (Supplementary
Figure S5c). The lack of mutations in these target sites
implies that the target region maybe functionally import-
ant. However, we observed several mutations in the
ﬂanking regions.
An HIV-1 anti-RNAi mechanism was encoded in the
Nef-30-LTR region
Our observation that the miR-223 and miR-29a/b/c
targets in the Nef-30-LTR region overlap with the putative
viral mir N367 coding sequence implies that this region
may not be easily accessible for miRISC due to the sec-
ondary structure of the region. This is also supported by
the PITA data (Table 3). It has been reported that the
local RNA structure of a siRNA target region is
Table 3. Cellular miRNA candidates for targeting the HIV-1 Nef-30-LTR (see excel ﬁle S2 for the complete data)—
PITA predicted host miRNA candidates that could effectively target the HIV-1 NL4-3 Nef-30-LTR region (see
Supplementary Table S2 for the complete data)
Host miRNA Position in
Nef-30-LTR
Position
in NL4-3
Seed Gduplex Gopen G
hsa-miR-24 68 8854 7:0:0  26.7  17.67  9.02
hsa-miR-29b 420 9206 8:0:0  26.3  22.85  3.44
hsa-miR-29a 420 9206 8:0:0  24.2  22.85  1.34
hsa-miR-29c 420 9206 8:0:0  22.5  22.85 0.35
hsa-miR-24 766 9552 7:0:0  19.7  22.01 2.31
hsa-miR-150 89 8875 6:0:0  19.2  20.34 1.14
hsa-miR-150 773 9559 6:0:0  17.66  18.27 0.61
hsa-miR-24 444 9230 6:0:0  16.24  10.63  5.6
hsa-miR-15a 724 9510 6:0:0  15.44  14.15  1.28
hsa-miR-24 503 9289 6:0:0  14.9  11.05  3.84
hsa-miR-15b 724 9510 6:0:0  14.54  14.15  0.38
hsa-miR-16 724 9510 6:0:0  14.2  14.15  0.05
hsa-miR-15a 156 8942 7:0:0  14.1  7.83  6.26
hsa-miR-16 156 8942 7:0:0  13.7  12.08  1.61
hsa-miR-15b 156 8942 7:0:0  12.7  12.08  0.61
hsa-miR-1224-3p 193 8979 8:0:0  30.5  7.89  22.6
hsa-miR-223 408 9194 6:0:0  19.4  15.86  3.53
In the seed column of the table, 8:0:0 represents the target site as an 8-mer seed with no mismatches, (middle ‘0’) and zero
G:U wobble pairs (right side ‘0’). Cellular miRNAs miR-29c, miR-1224 and miR-223 are presented for comparison
purposes and are not considered as candidates due to their low expression levels in CD4 T cells.
2186 Nucleic Acids Research, 2012,Vol.40, No. 5important for RNAi (61,62) and HIV-1 can mutate to
form alternate local structures which allow escape from
RNAi (59). To address whether the poor accessibility of
the target region plays a major role in blocking miR-29
mediated suppression, experiments were performed using
the dual-luciferase reporter assay.
The psiCheck
TM-2 Vector (Promega) was modiﬁed at
the multiple cloning sites (renamed psiCheck-2.2) and
was used to assay host miRNA effects on non-Nef
containing transcripts that harbor the target 30-UTR
(Figure 4a). (The pNL4-3-Luc reporter can only measure
the suppressive effect through 30-UTR targeting). In order
to directly measure the suppressive effects on Nef by
miR-223 or miR-29a/b, we created psiCheck-3.2 and
psiCheck-4.2 (Figure 4a and b).
Co-transfection assays with reporters harboring long
fragments from NL4-3 that span the target region
(siCheck2.2-C, D, E, F and siCheck3.2/4.2-A, B in
Figure 2. MiR-29 and miR-223 target region on HIV-1 Nef-30-LTR overlap with the N367 coding region. (a) Alignment of miR-223, 29 putative
targets and the putative HvmiR-N367 encoding region across all HIV-1 subtypes. (b) Base pairing of miR-223, 29a and 29b mature sequences with
the target region on the Nef-30-LTR consensus sequence.
Nucleic Acids Research,2012, Vol.40, No. 5 2187Figure 4b) resulted in weak repression with miR-223 and
miR-29a/b miRNAs when they target either the 30-UTRs
(Figure 5a) or the coding regions (Figure 5b), which is
consistent with the poor accessibility of this region as
calculated by PITA (Table 3). To test whether the weak
response is due to an intrinsic inability of the miRNAs to
mediate repression or to structural constraints, reporters
with short (39nt) sequences spanning the miR-223-29a/
b-N367 target region (H in Figure 4b) were tested.
Using this approach luciferase expression was strongly re-
pressed ( 60–80%) by the miR-29a/b miRNAs but
weakly repressed ( 5–10%) by miR-223. Reporters with
seed mutations in miR-223 or miR-29a/b targets speciﬁc-
ally abrogated the repression by the miRNAs in all cases
(Figure 5c). Extending the 39 bases of the target region to
56 bases (G in Figure 4b), which allows formation of a
hairpin structure resembling the stem-loop structure of
pre-miRNAs, resulted in a dramatic reduction in the re-
pression mediated by all the miRNAs tested (Figure 5d).
Taken together, these results strongly support the exist-
ence of a secondary structure in the native 30-UTR which
blocks accessibility of the miR-223 and miR29a/b. Since it
has been reported that a putative virally encoded miRNA
can be processed from this region we investigated whether
or not the block to miR29 function was possibly due to
processing the target from this region. To examine this
possibility northern blots probing for the putative viral
miRNA N367 were performed on RNA isolated from
NL4-3, NL4-3-Luc, HIV-1 IIIB-infected CEM and
Jurkat cells at Day 21 (N367 was originally discovered
in HIV-1 IIIB-infected cells). Probes for N367-3p/5p
failed to detect any complementary small RNAs in any
of these samples (data not presented). An mRNA
northern blot was also performed to detect the Rluc tran-
script reporter constructs, and these showed the fusion
transcripts to be intact (Supplementary Figure S6).
Mutations at nucleotides 9149, 9180 or both within the
9131-9241 region (E in Figure 4b) did not increase
miR-29 or miR-223 suppression in the psiCheck derivates,
suggesting that the secondary structure in this region is
very stable (data not shown). HIV-1 NL4-3 whole
genome structural analyses have shown this region forms
three hair-pin type structures (63). Thus, it appears that
HIV-1 has evolved secondary structures in this region
which in effect prevent host miRNAs from targeting this
region. Whether these structures evolved to escape host
miRNAs or for other functional reasons, the net result
is that potential miRNA mediated repression of HIV-1
protein expression is attenuated. The occurrence of muta-
tions in this region would potentially be deleterious to Nef
function since they would be within the Nef coding region.
The miR-29 seed complementary sequence (50-UGGUGC
U) encodes amino acids Tryptophan (the only amino acid
with an indole ring and encoded only by UGG) and
Cysteine (the only amino acid containing a thiol group
that can form a disulﬁde bond which is encoded by
UGC or UGU). Thus, mutations in the miR-29a/b seed
target which includes UGGUG may be functionally con-
strained from mutational changes.
The regulation of miR-223 expression in
HIV-1-infected cells
MiR-223 was initially identiﬁed as a hematopoietic-
speciﬁc miRNA predominately expressed in granulocyte
and macrophage lineages (64). The ﬁrst reported regula-
tion of miR-223 expression was shown by competitive
binding of activation factor C/EBP a and repression
factor NF-1A in the presumptive promoter region of a
1kb DNA fragment upstream of miR-223 (36) (p223c,
Supplementary Figure S7a). In addition, a long transcript
containing miR-223 has been reported in the GenBank
(accession number DQ680072). We identiﬁed a promoter
(p223a, Supplementary Figure S7a) located far upstream
of proposed the promoter site (36). The existence of both
the upstream p223a promoter and a more proximal
minimal promoter (p223b) were conﬁrmed by 50-RACE
analyses (65) (Supplementary Figure S7a). Interestingly,
this same group showed that C/EBP b can upregulate
pri-miR-223 expression via p223a. This observation
provides a possible explanation for the upregulation of
miR-223 in HIV-1-infected cells, since HIV-1 Tat, and
Vpr proteins are reported to activate C/EBP b (66,67).
To test this possibility we constructed reporters in which
various regions of the p223 promoter were fused to Fireﬂy
luciferase. We used this system to test the effects of co-
expressing various transcription factors in co-transfection
assays (Supplementary Figure S7b and c). Our data
indicate that C/EBP a but not b, upregulates expression
through p223a, with only minimal effects on expression
from p223c).
Our miR-223 target validation experiments showed
ATRA treatment induced miR-223 expression in NB4,
HL-60 and U937 cells, but not in CEM and Jurkat cells
(Supplementary Figure S4b and d). Therefore,
upregulation of miR-223 in HIV-1-infected CEM and
Jurkat cells is probably not due to HIV-1 encoded
proteins upregulating C/EBP a.
Another possible explanation for upregulation of
miR-223 levels after HIV-1 infection could be a conse-
quence of increased apoptosis (68), especially since
elevated levels of cell death were observed 4 days
post-ATRA treatments in the miR-223 target validation
experiments. Therefore, we measured the level of apop-
tosis in NB4 and U937 cells treated by ATRA for 3
days and observed that  30% of the cells went through
apoptosis (data not presented), which is consistent with
Table 4. Cellular miRNA candidates for targeting the HIV-1
Nef-30-LTR (see excel ﬁle S2 for the complete data)—Summary
of miR-223 and 29 target sites on NL4-3 genome
miRNA Seed (6-mer) Position
on NL4-3
Target
region
hsa-miR-223 ACUGAC 119 50-LTR
3924 Pol
5544 Vif
9194 Nef/30-LTR
hsa-miR-29a/b/c UGGUGC or
GGUGCU
132 50-LTR
9207 Nef/30-LTR
2188 Nucleic Acids Research, 2012,Vol.40, No. 5Figure 3. Reporter and P24 assays to test repression of HIV-1 NL4-3 by miR-223 and miR-29. (a) Co-transfection of pNL4-3-Luc with miRNAs.
The data show miR-223 has weak repression, miR-29 has somewhat better repression. MiRtron-1224 gave mild repression. The y-axis represents the
relative Fluc to Rluc signal (as percentages) normalized to the control (fU1-miR) by percentage. The values represent the average from at least three
independent experiments and the error bar represents the standard deviation. (b) HIV-1 P24 assays for co-transfection of HIV-1 pNL4-3 with
ectopically expressed pri-miRNA-223 or 29 in HeLa-T4 cells. The results indicate strong repression from miR-29 but not miR-223. The y-axis
represents the relative p24 values (as percentages) normalized to the control (fU1-miR). The values represent the average from at least three
independent experiments and error bar represents the standard deviation. (c) HIV-1 P24 assays for co-transfection of HIV-1 pNL4-3 with chemically
synthesized pre-miRNA-223, -29a, -29b and anti-miRs for miR-223, -29a, -29b into HeLa-T4 cells. The results indicate moderate repression mediated
by miR-29a, -29b and somewhat milder repression mediated by miR-223. The anti-miR data show an increase in P24 levels for anti-miR-29a and
anti-miR-29b, but not for anti-miR-223. The y-axis represents relative p24 values (as percentages) normalized to the control (Negative pre-miR as
control for pre-miRNAs and negative anti-miR as control for anti-miRs). The values represent the average from at least three independent experi-
ments and the error bars depict the standard deviation.
Nucleic Acids Research,2012, Vol.40, No. 5 2189Figure 4. Reporters used to test the repression of NL4-3 by miR-223 and miR-29. (a) Diagram of psiCHECK-2.2, psiCHECK-3.2 and
psiCHECK-4.2. PsiCHECK
TM-2 (Promega) was modiﬁed at the multiple cloning sites (MCS) and was renamed as psiCHECK-2.2. A target
fragment inserted in the MCS will produce a fusion transcript with Rluc and produce the normal Rluc protein. PsiCHECK-2.2 was further
modiﬁed to create psiCHECK-3.2 and psiCHECK-4.2. In -3.2, the stop codon of Rluc was mutated and the synthetic polyadenylation signal
was maintained at the 30 of the MCS. A target fragment inserted in the -3.2 MCS will produce a fusion transcript and a fusion Rluc protein
using stop codon and polyadenylation signal contained in the inserted fragment or the polyadenylation signal on -3.2. In -4.2, the stop codon of Rluc
was mutated and the synthetic polyadenylation signal was also removed. A target fragment inserted in the -4.2 MCS will produced a fusion transcript
and a fusion Rluc using the stop codon and polyadenylation signal contained in the inserted fragment. (b) Diagram of fragments used to construct
reporters to test the repression from miR-223 and miR-29 via binding the Nef-30-LTR. Fragments A (8897-9709) and B (9059-9709) were cloned into
psiCHECK-2.2, -3.2 and -4.2 to test miR-223 and miR-29 repression in Nef when it is translated (target coding sequence). Fragments C (8887-9241),
D (8887-9400), E (9131-9241), F (9131-9400), G (9172-9237) and H (9179-9227) were inserted into siCheck-2.2 to measure miR-223 and miR-29
repression of HIV-1 when Nef functions as a 30-UTR for other transcripts. We aligned miR-223, miR-29 target region and N367 encoding region in
Nef-30-LTR consensus sequence, NL4-3, HIV-1 IIIB, as well as sequences of the target region were mutated in miR-223 seed or miR-29 seed binding
sites. (c) QuikFold predicted structure for the miR-29 target region in the Nef-30-LTR. A longer fragment including the miR-29 target region in the
Nef-30-LTR was used for a structure prediction by QuikFold. QuikFold gave two structures (target region in lower case. Partial structures are
depicted).
2190 Nucleic Acids Research, 2012,Vol.40, No. 5Figure 5. Reporter assay tests for the repression of NL4-3 by miR-223 and miR-29. For all transfections, the values represent the average of at
least three independent experiments and the error bar represents the standard deviation. (a) Reporter assays show miR-223/29 repression is very
weak when Nef serves as the 30-UTR. (b) Reporter assays show miR-223/29 repression of Nef when it serves as a coding region. (c) Reporter assays
to measure the miR-223/29 repression using the 39nt target sequence. Co-transfection of the reporter and miRNA genes in HEK-293 cells show
weak repression by miR-223 and strong repression by miR-29. Mutated seed binding site for miR-223 or miR-29 abrogated the repressions mediated
by either miRNA. (d) Reporter assays to measure the miR-223/29 repression using a 56nt target sequence. Co-transfection of the reporter and
miRNA expression constructs in HEK-293 cells show weak repression mediated by miR-223 and reduced repression mediated by the miR-29
miRNAs.
Nucleic Acids Research,2012, Vol.40, No. 5 2191the above interpretation. We next treated several cell lines
with cisplatin (CDDT) or campothecin (CPT) to induce
apoptosis. We observed that CPT can increase miR-223
expression (Supplementary Figure S7e) suggesting that at
least part of the upregulation of miR-223 in HIV-1-
infected cells may be caused by HIV-1 induced apoptosis.
It has been reported that Nef can induce apoptosis in
HIV-1-infected cells by binding to and inhibiting ASK1,
a key player in apoptosis (69).
The regulation of miR-29a/b expression
MiR-29a was reported to be repressed by NF-kB acting
through YY1 and the Polycomb group proteins during
myogenesis (70). HIV-1 Tat can hyper-activate the expres-
sion of NF-kB by directly interacting with SIRT1 and
blocking SIRT1’s ability to deacetylate lysine 310 in the
p65 subunit of NF-kB (71). Thus Tat may repress
miR-29a through NF-kB. The accumulation of miR-29b
in the nucleus during mitosis has been reported (72). By
searching through computer predicted miR-29a/b targets,
we identiﬁed NASP (nuclear autoantigenic sperm protein)
as a potential miR-29a/b target (Supplementary Figure
S8a). NASP is reported to be an H1-speciﬁc histone chap-
erone and is cell cycle regulated (73,74). Decreased NASP
levels correlate with a decrease of cells in S-G2 phase.
Thus, upregulation of this protein may result in an
increase in G2 phase cells (75). We found reciprocal ex-
pression of miR-29b and NASP during the cell cycle:
miR-29b levels are high during mitosis whereas the level
of NASP is low (Supplementary Figure S8b). Since G2
phase arrest is associated with the expression of the
HIV-1 Vpr protein (31,76–78), Vpr could decrease
miR-29b, thereby facilitating HIV-1 infection. Reduction
of miR-29b would maintain NASP at a higher level and
arrest cells in the G2 phase. In this context it is also inter-
esting to note that another study reports that virion-
associated Vpr is required for efﬁcient Nef expression
from unintegrated HIV-1 proviral DNA (79). It would
therefore be of interest to determine if Vpr can upregulate
Nef via downregulating miR-29.
DISCUSSION
MiRNAs regulate protein expression via binding to the
30-UTR of complementary target mRNAs leading to trans-
lational inhibition and P-body mediated mRNA degrad-
ation. An intriguing problem is whether or not miRNAs
play a role in the regulation of HIV-1 gene expression,
either directly or indirectly, thereby affecting HIV-1 infec-
tion. The HIV-1 Nef-30-LTR region serves as the 30-UTR
for all HIV-1 transcripts. Thus, miRNA binding sites in
this region could potentially play critical roles in modulat-
ing the expression of proteins from multiple HIV-1 tran-
scripts during various stages of the HIV-1 replication
cycle. Nef expression may also be directly affected via tar-
geting the Nef coding region. Nef has been shown to play
an important role in viral replication and pathogenesis.
Nef can promote the degradation of CD4 and MHC
proteins to evade the host immune response to HIV-1.
Nef can also promote the long-term survival of infected
T cells and the destruction of non-infected by-stander T
cells. HIV-1 patients harboring strains with Nef gene de-
letions have slower progression to AIDS (80). Thus,
miRNAs targeting the Nef region have the potential to
affect HIV-1 pathogenesis.
Many host miRNAs target the Nef-30-LTR region
Huang et al. proposed that miR-28, miR-125b, miR-150,
miR-223 and miR-382 contribute to HIV-1 latency (8).
These miRNAs may be enriched in resting CD4 cells
relative to activated CD4 cells. The absolute expression
levels of most of these miRNAs in CD4 cells are modest
according to our miRNA microarray results and other
groups’ published large scale miRNA cloning data
(26,27) (Supplementary Figure S3). Based on PITA’s
data of the 256 seed match sites in the Nef-30-LTR con-
sensus sequence, the expression levels of miRNAs in CD4
T cells (Supplementary Figure S3b), and in combination
with the target site conservation and miRNA/target site
binding energies, we identiﬁed a list of host miRNAs
including miR-15a, 15b, 16, 24, 29a, 29b, 150 and 223
which could potentially target HIV-1 in the transcribed
30-LTR region. Such targeting could play a role in
modulating HIV-1 infection (Supplementary Figure S3b
and c) although our results suggest that direct targeting
of the HIV UTR by some of these miRNAs has at best a
weak inhibitory effect.
HIV-1 infection alters levels of host miRNAs
In the current study, our microRNA proﬁling revealed
that it is unlikely that HIV infection causes global
miRNA de-regulation since it more clearly affected the
levels of some but not all miRNAs. We were unable to
reproduce the array results that were published by either
Yeung et al. or Triboulet et al. (7,81). We were also unable
to reproduce their array and northern blot data showing
downregulation of the miR-17 clusters in either HIV-1
IIIB-infected Jurkat or CEM cells. Both miR-17-5p and
miR-20a probes did not demonstrate downregulation of
the corresponding miRNAs by northern or our array ana-
lyses (Supplementary Figure S2; Supplementary Table S1a
and b). Interestingly, Houzet et al. (9) observed down-
regulation of both miR-29a and 29b in both HIV-1
patients and in infected PBMCs, and downregulation of
miR-29c, miR-26a and miR-21 in HIV-1 patients. These
miRNAs were among those downregulated in our array
results. In contrast to the previously published array
analyses, our northern blots, TaqMan RT-PCR and the
LNA array version 11 results showed the upregulation of
miR-223. The results from Yeung et al., Triboulet et al.
and Houzet et al. were all produced with the RAKE
arrays. We used total RNA for the array, while they
used mirVana fractionated small RNAs for their array
analyses. Fractions of small RNAs for miRNA array ex-
periments may produce biased results as reported by Ach
et al. (82) from the Agilent miRNA array development
team. MiR-223 was also reported to be upregulated in
ATL patients and downregulated in HTLV-1 transformed
cell lines by mirVana miRNA bioarray and TaqMan
qRT-PCR (10,11).
2192 Nucleic Acids Research, 2012,Vol.40, No. 5The host miRNAs that can potentially interact directly
with HIV-1 RNA are miR-29a/b and 223. These miRNAs
are seed matched to a highly conserved region of HIV-1,
but these miRNAs may also play a role in regulation of
the cell cycle. HIV-1 Vpr induced G2 phase arrest in
infected cells could explain how HIV-1 infection
downregulates the miR-29 family. It has been previous
reported that miR-29 can target CDC42, a protein
involved in regulation of the cell cycle (48). It has been
reported that miR-29a/b are enriched in M phase and
miR-29b actually localizes to the nucleus (72). It is also
known that HIV-1 infection can arrest cells in G2 phase
(31,76,77). By blocking cells from entering M phase,
HIV-1 infection could reduce the expression of miR-29,
and it could be an inconsequential coincidence that
miR-29 has a seed match in the HIV-1 30-UTR.
Alternatively, miR-29 could be absorbed by a ‘sponge’
effect binding to the HIV-1 30-UTR as the HIV transcripts
enter the cytoplasm. Results published by Ahluwalia et al.
and Nathans et al. (12,83) showed miR-29a can target
HIV-1 through the Nef-30-LTR region. However the sec-
ondary structure of the HIV-1 LTR in the miR29a/b
target region appears to strongly attenuate this potential
interaction.
Our results showing that HIV-1 infection is accompan-
ied by downregulation of the miR-29 family implies that
this could lead to the upregulation of Nef and CDC42,
leading to apoptosis of CD4 cells. Based upon all of our
analyses, we propose a possible Vpr/Nef!apoptosis!
miR-223!Nef regulatory circuit. HIV-1 may require
Nef to induce apoptosis of non-infected CD4 T cells via
a bystander effect. The modulation of anti-apoptotic
factors could trigger upregulation of miR-223, which in
turn could downregulate Nef. Such a regulatory circuit
may preserve the survival of the infected cells thereby
ensuring survival of the virus itself. Our study of the in-
hibitory effect by miR-223 on HIV infection produced
results which are in conﬂict with a previously published
study (8). We ﬁnd the target site of miR-223 in HIV-1 to
be marginally effective when examined using reporters
with long sequences that ﬂank the miR-223 seed target.
Thus the contradiction between our results and those of
the previous study can be explained by the differences in
target sequence accessibility using short versus long HIV-1
30-UTR sequences in the reporter constructs. Such short
fragments clearly may not mimic the context of the target
in a full length UTR, which can take on secondary struc-
tures (84,85). The different inhibitory results obtained
from our reporters harboring 39 and 56nt long miR-
223/miR-29 target sequences which cannot or can respect-
ively form an inhibitory secondary structure clearly reﬂect
this possibility. Furthermore, we used the dual-luciferase
system with all reporters having Fluc as an internal
standard, whereas the previous study relied on FACS
analyses of EGFP which harbored the different target se-
quences. We believe the dual-luciferase system provides a
better measure of the miRNA mediated repression than a
single reporter or dual reporter system which uses two
separate plasmids.
Due to the low expression levels of miR-223 in T cells,
and the poor accessibility of the target site, it is unlikely
that miR-223 directly inhibits HIV-1 in these cells. The
expression of miR-223 is dramatically increased in myeloid
cells, especially in granulocytes, and it also potentially
targets other regions of the virus such as Pol and Vif in
addition to Nef. Thus it is possible that miR-223 could
have an inhibitory function on HIV-1 in NK cells, macro-
phages and monocytes. It is more likely though that
Figure 6. A map of the interactions between HIV-1, miR-223 and the miR-29 family.
Nucleic Acids Research,2012, Vol.40, No. 5 2193miR-223 inﬂuences HIV-1 infection by targeting cellular
factors required for replication, such as RhoB, Sp3 and
LIF.
In summary, we provide a detailed picture of the
possible functions of miRNAs whose levels are perturbed
in the acute phase of HIV-1 infection. Combining the
results from miR-223 and miR-29a/b target modulation,
we propose a possible regulatory network that is estab-
lished following HIV-1 infection, which primarily involves
these two host miRNAs (Figure 6). Further testing of this
model will be required to establish the validity of this
circuit of regulation of host factors that can affect HIV
replication and pathogenesis.
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